Lehmann Lehmann

Dr. Lehmann Lehmann


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LLLehmann Lehmann
Lehmann Lehmann
HPHelmut Prosch
Helmut Prosch
SZSonja Zehetmayer
Sonja Zehetmayer
MGMaximilian Robert Gysan
Maximilian Robert Gysan
DBDominik Bernitzky
Dominik Bernitzky
DGDaniela Gompelmann
Daniela Gompelmann
Background: Elevated D-dimer is known as predictor for severity of SARS-CoV2-infection. Increased D-dimer is associated with thromboembolic complications, but it is also a direct consequence of the acute lung injury seen in COVID-19 pneumonia. Objectives: To evaluate the rate of persistent elevated D-dimer and its association with thromboembolic complications and persistent ground glass opacities (GGO) after recovery from COVID-19. Methods: In this post hoc analysis of a prospective multicenter trial, patients underwent blood sampling, measurement of diffusion capacity, blood gas analysis, and multidetector computed tomography (MDCT) scan following COVID-19. In case of increased D-dimer (>0,5 μg/ml), an additional contrast medium-enhanced CT was performed in absence of contraindications. Results were compared between patients with persistent D-dimer elevation and patients with normal D-dimer level. Results: 129 patients (median age 48.8 years; range 19–91 years) underwent D-Dimer assessment after a median (IQR) of 94 days (64–130) following COVID-19. D-dimer elevation was found in 15% (19/129) and was significantly more common in patients who had experienced a severe SARS-CoV2 infection that had required hospitalisation compared to patients with mild disease (p = 0.049). Contrast-medium CT (n = 15) revealed an acute pulmonary embolism in one patient and CTEPH in another patient. A significant lower mean pO2 (p = 0.015) and AaDO2 (p = 0.043) were observed in patients with persistent D-Dimer elevation, but the rate of GGO were similar in both patient groups (p = 0.33). Conclusion: In 15% of the patients recovered from COVID-19, persistent D-dimer elevation was observed after a median of 3 months following COVID-19. These patients had experienced a more severe COVID and still presented more frequently a lower mean pO2 and AaDO2.

5 September 2021 in European Respiratory Journal
Verified
Conference Paper
Closed access
LLLehmann Lehmann
Lehmann Lehmann
HPHelmut Prosch
Helmut Prosch
SZSonja Zehetmayer
Sonja Zehetmayer
MGMaximilian Robert Gysan
Maximilian Robert Gysan
MIMarco Idzko
Marco Idzko
DGDaniela Gompelmann
Daniela Gompelmann
Elevated D-dimer is known as predictor for severity of SARS-CoV2-infection. Thereby, elevated D-dimer is associated with thromboembolic complications, but it is also a direct consequence of the acute lung injury seen in COVID-19 pneumonia. To evaluate the rate of persistent elevated D-dimer and its association with thromboembolic complications and persistent ground glass opacities (GGO) after recovery from COVID-19. In this post hoc analysis of a prospective multicenter trial, patients underwent blood sampling, measurement of diffusion capacity, blood gas analysis and multidetector computed tomography (MDCT) scan following COVID-19. In case of increased D-dimer (>0,5 µg/ml), an additional contrast medium-enhanced CT was performed in absence of contraindications. Results were compared between patients with persistent D-dimer elevation and patients with normal D-dimer. 129 patients (median age 48.8 years; range 19-91 years) underwent D-Dimer assessment after a median (IQR) of 94 days (64-130) following COVID-19. D-dimer elevation was found in 15% (19/129) and was significantly more common in patients who had experienced a severe SARS-CoV2 infection that had required hospitalisation compared to patients with mild disease (p=0.049). Contrast-medium CT (n=15) revealed an acute pulmonary embolism in one and CTEPH in another patient. A significant lower mean pO2 (p=0.015) and AaDO2 (p=0.043) were observed in patients with persistent D-Dimer elevation, but the rate of GGO were similar in both patient groups (p=0.33) In 15% of the patients recovered from COVID-19, persistent D-dimer elevation was observed after a median of 3 months following COVID-19. Those had a more severe COVID and still a lower mean pO2 and AaDO2.

5 September 2021 in European Respiratory Journal
Verified
Conference Paper
Closed access
LLLehmann Lehmann
Lehmann Lehmann
MGMaximilian Gysan
Maximilian Gysan
DBDominik Bernitzky
Dominik Bernitzky
HPHelmut Prosch
Helmut Prosch
MIMarco Idzko
Marco Idzko
DGDaniel Gompelmann
Daniel Gompelmann
Multiple studies report persistent symptoms following SARS-CoV-2 infection including fatigue, dyspnoea, headache, chest tightness and cough (e.g. Carfi, A. et al. JAMA 2020; 324(6):603-605). Frequency and prognosis of respiratory symptoms, limitations in lung function and persistent changes of lung parenchyma on high-resolution computed tomography (HRCT) following SARS-CoV-2 infection remain unclear. The objective of this study is to determine whether patients develop structural lung disease after recovery from COVID-19. We conduct an ongoing multicentric prospective study assessing patients after confirmed COVID-19. Patients undergo lung function tests and low-dose HRCT at baseline and after 3, 6 and 12 months. In this preliminary analysis, 158 patients aged 47.4 ± 15.8 years (range, 19-91 years) were identified. 44 patients were previously hospitalized. The median hospitalization was 11 days (range, 1-61 days). 65.9% of hospitalized patients (n=29) required oxygen therapy and 11.4% (n=5) required intensive care treatment. Lung function was assessed 17-291 days after confirmed COVID-19 with a median of 82 days. 15.8% of patients showed a reduced FVC < 80% and an impairment in TLC (TLC < lower limit of normal) could be detected in 8.3% of the cases. 40.9% of patients showed a reduction in diffusion capacity (TLCO) and in 13% the transfer coefficient (TLCO/VA) was reduced. Typical CT sings of COVID-19 pneumonia were observed in 32.7% of patients 9-303 days after confirmed COVID-19 with a median of 82 days. In a sample of 158 patients with confirmed COVID-19, one third showed persistent changes on HRCT and a reduction in diffusion capacity approximately 3 months after disease onset.

Verified
Journal Article
Open access
PDF file
MGMaximilian Gysan
Maximilian Gysan
KKKastriot Kastrati
Kastriot Kastrati
SPSvitlana Pochepnia
Svitlana Pochepnia
HPHelmut Prosch
Helmut Prosch
LLLehmann Lehmann
Lehmann Lehmann
HRHelga Radner
Helga Radner
Background: Systemic autoimmune rheumatic diseases-associated interstitial lung disease (SARD-ILD) presents with varied disease courses, emphasizing the need for reliable predictors of progression. The prognostic utility of bronchoalveolar lavage (BAL) in SARD-ILD remains underexplored. The objective of this study was to evaluate the role of BAL fluid lymphocyte count in predicting disease progression in patients with SARD-ILD. Methods: This observational study included patients with SARD-ILD undergoing BAL as part of their diagnostic workup. Disease progression was defined as either Forced vital capacity (FVC) decrease >10%, two out of the following three criteria within two years: FVC decrease of 5–10%, worsening symptoms, increased fibrosis on imaging, or any of the following: escalation of treatment, Interstitial lung disease (ILD) exacerbation, lung transplantation, or disease-specific mortality. Logistic regression identified predictors of progression. Time-to-progression was assessed using Kaplan–Meier survival curves. The optimal BAL lymphocyte threshold for predicting progression was identified using the Youden Index and the Wilcoxon method. Results: We identified 89 patients, of whom 30 (33.7%) had progressive disease. Progressors had a significantly higher BAL lymphocyte count compared to non-progressors (31.6 ± 24.8% vs. 14.3 ± 16.5%, p < 0.001). BAL lymphocyte proportion was significantly and independently associated with disease progression (odds ratio, 1.05; 95% confidence interval 1.02–1.07; p < 0.01). A lymphocyte count above 9 percent was associated with a markedly increased risk of disease progression (odds ratio, 13.14; 95% confidence interval, 4.20–51.98; p < 0.01). Conclusions: BAL lymphocyte count was associated with a higher likelihood of progression in SARD-ILD. BAL assessment may help identify patients at increased risk of disease progression. However, these findings should be considered exploratory and require validation in larger prospective studies and across individual SARD-ILD subtypes.